The MAGNETOM Viato.Mobile may facilitate improved access to MRI capabilities for patients with serious health conditions who lack geographic proximity to centers with advanced imaging.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the MAGNETOM Viato.Mobile, a 1.5 Tesla magnetic resonance imaging (MRI) system that is reportedly designed for easy transportation to off-site locations.
The 70 centimeter-bore scanner offers a variety of features including BioMatrix Technology and Deep Resolve image reconstruction, according to Siemens Healthineers, the manufacturer of MAGNETOM Viato.Mobile.
The company said the artificial intelligence (AI)-powered Deep Resolve technology accelerates scan times for brain scans by up to 70 percent, enhances image resolution and improves signal-to-noise ratio. Siemens Healthineers added that BioMatrix Technology prevents variation in imaging results by enabling clinicians to personalize MRI exams and compensate for different patient anatomies and physiologies.
Jane Kilkenny, the vice president of magnetic resonance at Siemens Healthineers North America, said the MAGNETOM Viato.Mobile represents an opportunity to bring the capabilities of advanced imaging to patients who don’t have geographic proximity to facilities with these imaging systems.
“The MAGNETOM Viato.Mobile demonstrates our dedication to the mobile MR market by offering the latest and greatest technologies to patients who might lack convenient access to premium diagnostic MR scanners,” noted Kilkenny. “The introduction of the MAGNETOM Viato.Mobile is yet another example of our efforts to democratize high-end imaging technology to provide greater access to care.”
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.